10-Q: Gaxos.AI Reports Q1 2026 Results: Revenue Surges, Net Loss Widens

Gaxos.AI Inc. reported a significant increase in revenue for the first quarter of 2026, driven by its RNK Health and Gaxos Labs subscription services, though net loss also widened due to increased operating expenses.

Summary

• Gaxos.AI Inc. reported revenues of $1,809,367 for the three months ended March 31, 2026, a substantial increase from $23,732 in the same period of 2025.
• The company's net loss for the quarter was $2,474,246, compared to a net loss of $1,232,062 in the prior year's quarter.
• Operating expenses increased significantly to $4,356,489 from $1,415,427 in the prior year, primarily due to higher research and development and general and administrative costs.
• Cash and cash equivalents increased to $1,513,550 as of March 31, 2026, from $840,799 as of December 31, 2025.
• The company raised approximately $5.3 million in net proceeds from the sale of common stock through an At The Market (ATM) offering during the quarter.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the significant increase in net loss and operating expenses, despite strong revenue growth. The widening loss indicates that current growth is not yet translating into profitability.

Positives

• Revenue increased dramatically by over 7,500% to $1,809,367 in Q1 2026 from $23,732 in Q1 2025, driven by administrative services from RNK Health and subscription services from Gaxos Labs.
• Cash and short-term investments combined increased to $11,709,341 as of March 31, 2026, from $13,225,986 as of December 31, 2025, indicating a strong liquidity position.
• The company successfully raised approximately $5.3 million in net proceeds from an ATM offering, bolstering its cash position.
• Working capital improved to $11,587,582 as of March 31, 2026, from $11,919,230 as of December 31, 2025.

Negatives

• Net loss widened by 100.8% to $2,474,246 for the three months ended March 31, 2026, from $1,232,062 in the same period of 2025.
• Operating expenses surged by 207.8% to $4,356,489 in Q1 2026 from $1,415,427 in Q1 2025.
• Research and development expenses increased by 102.0% to $446,422 from $220,989.
• General and administrative expenses increased by 227.4% to $3,910,067 from $1,194,438, largely due to a significant increase in advertising and marketing costs.
• Net loss per common share increased to $(0.25) from $(0.17) year-over-year.

Risks

• The company's telehealth business, through its subsidiary RNK Health, could be adversely affected by ongoing legal challenges to telehealth business models or new state actions restricting services.
• Evolving government regulations and enforcement activities in the telehealth space may require increased costs or adversely affect results of operations.
• The company's ability to obtain additional funds for operations and to achieve and sustain profitability remains a key risk.
• Competition from existing players and new market entrants in the AI and technology sectors poses a significant challenge.
• The company's financial performance, including revenues, cost of revenues, and operating expenses, is subject to considerable uncertainty.

Future Outlook

The company expects to continue generating operating losses in the foreseeable future due to corporate overhead, R&D, and public company costs. However, it believes its existing working capital and cash on hand will be sufficient to meet operating needs for the next twelve months. The company plans to pursue research and development of its products, which will require resources beyond current holdings and likely necessitate additional third-party financing.

Management Comments

• Gaxos.AI is building a portfolio of AI-powered solutions designed to make advanced technology more practical, accessible, and transformative.
• The company expects research and development expenses to increase in the future as development of Gaxos Labs, Gaxos Health, and RNK Health accelerates.
• We believe that our existing working capital and cash on hand will provide sufficient cash to enable the Company to meet its operating needs and debt requirements for the next twelve months from the issuance date of this report.

Industry Context

StockSavvy.ai notes that Gaxos.AI's significant revenue growth in Q1 2026, particularly from its RNK Health and Gaxos Labs initiatives, aligns with broader industry trends of increasing adoption of AI in healthcare and software-as-a-service models. However, the widening net loss highlights the high cost of scaling these ventures and the competitive landscape in the AI sector.

Comparison to Industry Standards

• While Gaxos.AI's revenue growth is substantial, its net loss per share of $(0.25) for Q1 2026 is a key metric to monitor. Many early-stage AI companies experience significant losses during development and market penetration phases, but investors will look for a path to profitability.
• The company's operating expenses as a percentage of revenue are very high ($4.36M expenses vs $1.81M revenue), indicating a need for greater revenue generation efficiency or cost control as it scales.
• Competitors in the AI development space, such as OpenAI or Google's AI divisions, often operate with substantial R&D budgets and may have different revenue models or funding structures, making direct comparison challenging without more specific market data for Gaxos.AI's niche products.

Legal Proceedings

• The company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceeding that could have a material adverse effect.

Related Party Transactions

• On October 10, 2024, the Company, RNK Health, and Nekwellness entered into an operating agreement for RNK Health, with Nekwellness owning a 30% membership interest in RNK Health in exchange for services.

Stakeholder Impact

• Shareholders: The widening net loss and increased operating expenses may negatively impact shareholder value in the short term, although the successful ATM offering provides liquidity.
• Employees: Continued investment in R&D and expansion may lead to job creation, but the company's financial performance could affect long-term stability.
• Customers: The company is expanding its AI-powered solutions in health, gaming, and productivity, potentially offering innovative tools and services.
• Creditors: The company's liquidity position and ability to meet obligations appear adequate for the next twelve months, but future financing needs could impact debt holders.

Next Steps

• Continue development and launch of AI applications across various sectors (Gaxos Labs, Gaxos Health, Gaxos Gaming).
• Implement growth strategy to achieve profitability.
• Pursue additional debt or equity financing if necessary to sustain operations and fund long-term business plans.
• Monitor and adapt to evolving government regulations in the telehealth sector.

Key Dates

Recommendation

The company shows strong revenue growth potential with its AI initiatives, but the significant increase in net loss and operating expenses warrants caution. The successful capital raise provides a buffer, but a clear path to profitability is not yet evident. Investors should hold and monitor future performance and cost management.

Keywords

Gaxos.AI, Form 10-Q, Quarterly Report, AI, Artificial Intelligence, Technology, RNK Health, Gaxos Labs, Gaxos Gaming, Financial Results, Revenue, Net Loss, Operating Expenses, SEC Filing